@article{Kotagiri_P-2022_133486,
title = {The impact of hypoxia on B cells in COVID-19},
author = {Kotagiri, P. and Mescia, F. and Hanson, A. and Turner, L. and Bergamaschi, L. and Peñalver, A. and Richoz, N. and Moore, S. and Ortmann, B. and Dunmore, B. and Morgan, M. and Tuong, Z. and Göttgens, B. and Toshner, M. and Hess, C. and Maxwell, P. and Clatworthy, M. and Nathan, J. and Bradley, J. and Lyons, P. and Burrows, N. and Smith, K. and Cambridge Institute of Therapeutic Immunology and Infectious Disease-National Institute of Health Research (CITIID-NIHR) Covid BioResource Collaboration},
month = {feb},
year = {2022},
abstract = {Prominent early features of COVID-19 include severe, often clinically silent, hypoxia and a pronounced reduction in B cells, the latter important in defence against SARS-CoV-2. This presentation resembles the phenotype of mice with VHL-deficient B cells, in which Hypoxia-Inducible Factors are constitutively active, suggesting hypoxia might drive B cell abnormalities in COVID-19.},
volume = {77},
journal = {eBioMedicine},
publisher = {Elsevier},
url = {https://doi.org/10.1016/j.ebiom.2022.103878},
}
